260 related articles for article (PubMed ID: 33466893)
1. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
[TBL] [Abstract][Full Text] [Related]
2. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
[No Abstract] [Full Text] [Related]
3. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
4. List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study.
Pan J; Wei X; Lu H; Wu X; Li C; Hai X; Lan T; Dong Q; Yang Y; Jakovljevic M; Zhou J
Lancet Reg Health West Pac; 2024 Jun; 47():101088. PubMed ID: 38774422
[TBL] [Abstract][Full Text] [Related]
5. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
Vogler S; Vitry A; Babar ZU
Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
[TBL] [Abstract][Full Text] [Related]
6. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
8. Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison.
Lee JH
Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33800373
[TBL] [Abstract][Full Text] [Related]
9. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
[TBL] [Abstract][Full Text] [Related]
10. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
[TBL] [Abstract][Full Text] [Related]
11. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
12. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.
Kwon HY; Kim H; Godman B
Front Pharmacol; 2018; 9():938. PubMed ID: 30233363
[No Abstract] [Full Text] [Related]
13. Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan.
Okabe A; Hayashi H; Maeda H
Curr Oncol; 2023 Feb; 30(2):1776-1783. PubMed ID: 36826098
[TBL] [Abstract][Full Text] [Related]
14. International price comparisons of Alzheimer's drugs: a way to close the affordability gap.
Suh GH; Wimo A; Gauthier S; O'Connor D; Ikeda M; Homma A; Dominguez J; Yang BM;
Int Psychogeriatr; 2009 Dec; 21(6):1116-26. PubMed ID: 19735595
[TBL] [Abstract][Full Text] [Related]
15. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.
Garattini L; Motterlini N; Cornago D
Health Policy; 2008 Mar; 85(3):305-13. PubMed ID: 17928092
[TBL] [Abstract][Full Text] [Related]
16. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
17. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
18. [Drug prices in Switzerland: European comparison of "comfort" drugs].
Vogt N; Morabia A; Dayer P
Schweiz Med Wochenschr; 1993 Nov; 123(47):2251-4. PubMed ID: 8272798
[TBL] [Abstract][Full Text] [Related]
19. A comparison of generic drug prices in seven European countries: a methodological analysis.
Wouters OJ; Kanavos PG
BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]